Pfizer asks FDA to clear COVID shots for babies

Pfizer has submitted a request to the FDA – which tried to hide Pfizer's clinical trial data for 75 years – to grant emergency use authorization to administer its COVID-19 vaccine to children from six months to 5 years of age.

While science shows kids don’t need jab, vaccines ineffective, risky

Art Moore
WND News Center

Children statistically have virtually no chance of death or serious illness from COVID-19, but, in any case, the experimental vaccines rushed to market under emergency use authorization have proven to be ineffective against the current SARS-CoV-2 variants while posing the risk of severe harm or death in proportions far higher than any vaccine in history.

Children also, according to studies, are at low risk of spreading COVID-19. Further, the CDC recently reported higher COVID-19 case rates have been recorded among fully vaccinated children than unvaccinated in the age group 5-11 since February 2022. And the U.K.’s Office for National Statistics found children are up to 52 times more likely to die following the COVID-19 injection than children who have not received it.

Nevertheless, Pfizer has submitted a request to the FDA – which tried to hide Pfizer’s clinical trial data for 75 years – to grant emergency use authorization to administer its COVID-19 vaccine to children from six months to 5 years of age.

The pharmaceutical giant declared in May that a three-shot regimen of its Pfizer-BioNTech vaccine was 80.3% effective in preventing COVID infections among children under 5, based on early results of its trial for that cohort.

An FDA advisory committee meeting is scheduled for June 15 in which experts will discuss the efficacy and possible side effects of the vaccine. The panel then will vote on whether or not to recommend that the FDA grant authorization.

In May, despite Pfizer trial data showing the chance of death in children from the shot is 107 times higher than death from COVID-19, the FDA approved Pfizer booster shots for children 5-11.

Members of the FDA’s vaccine advisory panel last fall reluctantly recommended approval of the Pfizer-BioNTech COVID-19 vaccine for children ages 5-11 amid a lack of safety data.

A panel member, Dr. Eric Rubin, editor of the New England Journal of Medicine, famously said during the hearing, “We’re never going to learn about how safe the vaccine is unless we start giving it – that’s just the way it goes.”

Should the FDA approve Pfizer's request to grant emergency use authorization to administer its COVID-19 vaccine to children from six months to 5 years of age?
329 votes

Also read:

Receive comment notifications
Notify of
guest

0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x
0
Would love your thoughts, please comment.x
()
x